• What if you could say,

    Remember Alzheimer's?

    Help us make history by making Alzheimer's history

  • DONATE NOW

    Researchers at the University of Alberta Hospital believe they have found a way to restore memory in the minds of Alzheimer’s patients.

     

    Your generosity will help them prove it.

    About Alzheimer's

    Researchers around the world are trying to solve the mystery of Alzheimer’s disease.

     

    At stake are the lives of millions of future and current Alzheimer’s patients.

     

    And the millions more family members and caregivers who must bear the excruciating toll of the long, slow deterioration of the mind of a loved one.

     

    That’s why this research is so important – and why your investment will help get us to the clinical trials needed to advance its progress.

    Project Background

     

    After working for more than 20 years in the search for a cure or effective treatment for Alzheimer’s disease, Dr. Jack Jhamandas, renowned neurologist and researcher at the University of Alberta Hospital, and his team which includes internationally recognized researchers Dr. Lorne Tyrell, who developed the first drug to treat Hepatitis B, and Dr Michael Houghton, who discovered the Hepatitis C virus, have made a significant discovery in a study that moves the medical world closer than ever to reducing the enormous impact of Alzheimer’s, the most common form of dementia, on millions of patients and their families.

    Amazing Discovery

     

    The study, as published in the journal, Scientific Reports, found that mice with Alzheimer’s disease showed considerable memory improvement after receiving daily injections of a particular string of amino acids, also known as peptides, for five weeks.

     

    Dr. Jhamandas reports that after the five weeks, there was less amyloid plaque buildup and inflammation in the brains of the mice. “This was very interesting and exciting because it showed us that not only was memory being improved in the mice, but signs of brain pathology in Alzheimer’s disease were also greatly improved.”

    The Next Step

     

    In order to begin clinical trials on humans, Dr. Jhamandas and his team are first working on developing a small molecule drug in a pill form that’s based upon the amino acid compound (peptide) that worked so well on the mice.

     

    Work has begun on this critical phase of the project, but it’s time consuming and extremely costly. That’s why securing long term funding to keep the project moving forward is so important.

     

    Competition for research grants – especially for projects of this magnitude, which could help millions of people around the world – is fierce. The application process is lengthy and demanding. The likelihood of success unknown until the results are shared – which can take months.

     

    That’s months of not knowing whether the project can proceed or not, meaning more time for Dr. Jhamandas to spend at the computer writing grant applications and less time in the research lab.

     

    Generous ongoing support from the community would allow Dr. Jhamandas and his team to develop the pill they need to begin human clinical trials sooner, and move that much closer to finding a way to minimize the devastating impact of Alzheimer’s disease.

     

    We hope you’ll consider an investment in this truly groundbreaking project.

    For more information,
    please contact: Caroline Thompson

    Caroline.Thompson2@ahs.ca | 780.407.7686

  • .

    "...not only was memory being improved in the mice, but signs of brain pathology in Alzheimer’s disease were also greatly improved.”

     

    .

    .

    .

  •  

    University Hospital Foundation © 2020

    Phone: 780-407-7007 | Fax: 780-407-8219 | email: uhfoundation@albertahealthservices.ca

    Charitable Registration Number 88900-3240 RR0001